# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

File	d by the	Registrant 🗵			
File	d by a l	arty other than the Registrant $\Box$			
Che	ck the a	ppropriate box:			
	Defir Defir	inary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by tive Proxy Statement  tive Additional Materials  ing Material Pursuant to §240.14a-12  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
		Amgen Inc.			
		(Name of Registrant as Specified In Its Charter)			
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)			
Payı	nent of	Filing Fee (Check the appropriate box):			
X	No f	No fee required.			
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.				
	(1)	Title of each class of securities to which transaction applies:			
	(2)	Aggregate number of securities to which transaction applies:			
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):			
	(4)	Proposed maximum aggregate value of transaction:			
	(5)	Total fee paid:			
	Fee I	Fee paid previously with preliminary materials.			
		box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid ously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.  Amount Previously Paid:			
	(2)	(2) Form, Schedule or Registration Statement No.:			
	(3)	8) Filing Party:			
	(4)	t) Date Filed:			

#### **SAMPLE**

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting To Be Held on May 22, 2013 at 11:00 A.M. Local Time of

### AMGEN INC.

Four Seasons Hotel Westlake Village, Two Dole Drive, Westlake Village, CA 91362

COMPANY NUMBER		
ACCOUNT NUMBER		
CONTROL NUMBER		

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before May 10, 2013.

Please visit http://www.amstock.com/ProxyServices/Amgen, where the following materials are available for view:

. Notice of 2013 Annual Meeting of Stockholders

 Proxy Statement . Form Proxy Card 2012 Annual Report

TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen

instructions. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time

on May 21, 2013.

IN PERSON: You may vote your shares in person by attending the Annual Meeting. If you wish to attend the

Annual Meeting, please visit http://www.seeuthere.com/AnnualMeeting2013 to register

TELEPHONE: To vote by telephone, please visit https://secure.amstock.com/voteproxy/login2.asp to

view the materials and to obtain the toll free number to call.

MAIL: You may request a proxy card by following the instructions below.

TO REQUEST MATERIAL: TELEPHONE: 888-Proxy-NA (888-776-9962) and 718-921-8562 (for international callers)

E-MAIL: info@amstock.com

WEBSITE: http://www.amstock.com/proxyservices/requestmaterials.asp

The Board of Directors recommends a vote "FOR" each listed nominee in Item #1.

The Board of Directors recommends a vote "FOR" each of Items #2, #3 and #4.

1.To elect thirteen directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2014 annual meeting of stockholders. The nominees for election to the Board are:

NOMINEES: Dr. David Baltimore Mr. Frank J. Blondi, Jr. Mr. Robert A. Bradway

Mr. François de Carbonnel Dr. Vance D. Coffman Mr. Robert A. Eckert Dr. Rebecca M. Henderson Mr. Frank C. Herringer

Dr. Tyler Jacks Dr. Gilbert S. Omenn Ms. Judith C. Pelham

Mr. Leonard D. Schaeffer Dr. Ronald D. Sugar

- 2. To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2013.
- 3. Advisory vote to approve our executive compensation
- 4. Approval of our proposed Amended and Restated 2009 Equity Incentive Plan.

Please note that you cannot use this notice to vote by mail.